Patient Journey in patients with fibrosing ILDs in Japan - A National Database Study

Patient Journey in patients with fibrosing ILDs in Japan - A National Database Study - Fibrosing ILDs related patient Journey, Japan (NDB)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059749

Enrollment

200000

Registered

2025-12-01

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IPF, PPF, and non-progressive ILD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with at least 2 fibrosing ILD codes in different months during the patient identification period Patients aged 20 years or older on the index date Patients for whom data for the 12 months prior to the index date can be extracted as baseline data

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To describe patient journey in patients with fibrosing Interstitial Lung Diseases (ILDs) in Japan.	—

Secondary

Measure	Time frame
To describe baseline demographic and clinical characteristics in patients with fibrosing ILDs in Japan. To investigate the initial symptoms prior to the diagnosis of fibrosing ILDs in patients with fibrosing ILDs in Japan. To investigate the time from the development of Progressive Pulmonary Fibrosis (PPF) to initiation of the PPF treatment in patients with PPF in Japan. To investigate the proportions of patients having each of the Idiopathic Pulmonary Fibrosis (IPF) and PPF treatments in patients with IPF and PPF in Japan. To investigate the time from PPF treatment to death in patients with PPF in Japan. To investigate the proportions of patients meeting each PPF criterion among those meeting any of the 9 PPF criteria in Japan.	—

Measure

Time frame

To describe baseline demographic and clinical characteristics in patients with fibrosing ILDs in Japan. To investigate the initial symptoms prior to the diagnosis of fibrosing ILDs in patients with fibrosing ILDs in Japan. To investigate the time from the development of Progressive Pulmonary Fibrosis (PPF) to initiation of the PPF treatment in patients with PPF in Japan. To investigate the proportions of patients having each of the Idiopathic Pulmonary Fibrosis (IPF) and PPF treatments in patients with IPF and PPF in Japan. To investigate the time from PPF treatment to death in patients with PPF in Japan. To investigate the proportions of patients meeting each PPF criterion among those meeting any of the 9 PPF criteria in Japan.

—

Countries

Japan

Contacts

Public ContactTsuyoshi Ishii

Nippon Boehringer Ingelheim Co., Ltd. Medicine Division

tsuyoshi.ishii@boehringer-ingelheim.com03-6417-2780

Outcome results